Document Classification

Section Type: RESULTS

Text: Mean reductions from baseline to week 13 for lumiracoxib 100mg od, 100mg od with loading dose, celecoxib and placebo, respectively, were : OA pain intensity in the target knee : 26. 8, 26. 2, 26. 6 and 21. 4 mm (all p < 0. 01 vs. placebo) ; patient 's global assessment of disease activity : 25. 1, 21. 9, 22. 9 and 18. 9 mm (all p < 0. 05 vs. placebo) ; WOMAC total score : 15. 2, 14. 8, 14. 7 and 11. 3 (all p < 0. 01 vs. placebo).